131 related articles for article (PubMed ID: 38047403)
21. Liver fibrosis promotes immune escape in hepatocellular carcinoma via GOLM1-mediated PD-L1 upregulation.
Ke MY; Xu T; Fang Y; Ye YP; Li ZJ; Ren FG; Lu SY; Zhang XF; Wu RQ; Lv Y; Dong J
Cancer Lett; 2021 Aug; 513():14-25. PubMed ID: 33992711
[TBL] [Abstract][Full Text] [Related]
22. Glycolytic activation of peritumoral monocytes fosters immune privilege via the PFKFB3-PD-L1 axis in human hepatocellular carcinoma.
Chen DP; Ning WR; Jiang ZZ; Peng ZP; Zhu LY; Zhuang SM; Kuang DM; Zheng L; Wu Y
J Hepatol; 2019 Aug; 71(2):333-343. PubMed ID: 31071366
[TBL] [Abstract][Full Text] [Related]
23. HKDC1 promotes tumor immune evasion in hepatocellular carcinoma by coupling cytoskeleton to STAT1 activation and PD-L1 expression.
Zhang Y; Wang M; Ye L; Shen S; Zhang Y; Qian X; Zhang T; Yuan M; Ye Z; Cai J; Meng X; Qiu S; Liu S; Liu R; Jia W; Yang X; Zhang H; Zhong X; Gao P
Nat Commun; 2024 Feb; 15(1):1314. PubMed ID: 38351096
[TBL] [Abstract][Full Text] [Related]
24. SRSF10 facilitates HCC growth and metastasis by suppressing CD8
Luo X; Zhang Z; Li S; Wang Y; Sun M; Hu D; Jiang J; Wang Y; Ji X; Chen X; Zhang B; Liang H; Li Y; Liu B; Xu X; Wang S; Xu S; Nie Y; Wu K; Fan D; Liu D; Huang W; Xia L
Int Immunopharmacol; 2024 Jan; 127():111376. PubMed ID: 38113691
[TBL] [Abstract][Full Text] [Related]
25. BCLAF1 binds SPOP to stabilize PD-L1 and promotes the development and immune escape of hepatocellular carcinoma.
Yu Z; Wu X; Zhu J; Yan H; Li Y; Zhang H; Zhong Y; Lin M; Ye G; Li X; Jin J; Li K; Wang J; Zhuang H; Lin T; He J; Lu C; Xu Z; Zhang X; Li H; Jin X
Cell Mol Life Sci; 2024 Feb; 81(1):82. PubMed ID: 38340178
[TBL] [Abstract][Full Text] [Related]
26. C-X-C chemokine receptor 2 (Cxcr2) promotes hepatocellular carcinoma immune evasion via regulating programmed death-ligand 1 (PD-L1).
Wan Y; Ge K; Zhou W; Lu J; Jia C; Zhu H
Biol Chem; 2021 May; 402(6):729-737. PubMed ID: 33583159
[TBL] [Abstract][Full Text] [Related]
27. KDM1A Promotes Immunosuppression in Hepatocellular Carcinoma by Regulating PD-L1 through Demethylating MEF2D.
Wang Y; Cao K
J Immunol Res; 2021; 2021():9965099. PubMed ID: 34307695
[TBL] [Abstract][Full Text] [Related]
28. Blocking Triggering Receptor Expressed on Myeloid Cells-1-Positive Tumor-Associated Macrophages Induced by Hypoxia Reverses Immunosuppression and Anti-Programmed Cell Death Ligand 1 Resistance in Liver Cancer.
Wu Q; Zhou W; Yin S; Zhou Y; Chen T; Qian J; Su R; Hong L; Lu H; Zhang F; Xie H; Zhou L; Zheng S
Hepatology; 2019 Jul; 70(1):198-214. PubMed ID: 30810243
[TBL] [Abstract][Full Text] [Related]
29. Histone deacetylase 2 regulates STAT1-dependent upregulation of atypical chemokine receptor 3 to induce M2 macrophage migration and immune escape in hepatocellular carcinoma.
Chen F; Yang L; Peng X; Mao M; Liu X; Song J; Hu J
Mol Immunol; 2022 Nov; 151():204-217. PubMed ID: 36179603
[TBL] [Abstract][Full Text] [Related]
30. Dickkopf-1 drives tumor immune evasion by inducing PD-L1 expression in hepatocellular carcinoma.
Yang RH; Qin J; Cao JL; Zhang MZ; Li YY; Wang MQ; Fang D; Xie SQ
Biochem Pharmacol; 2023 Feb; 208():115378. PubMed ID: 36513141
[TBL] [Abstract][Full Text] [Related]
31. Targeting of GSDMD sensitizes HCC to anti-PD-1 by activating cGAS pathway and downregulating PD-L1 expression.
Lv T; Xiong X; Yan W; Liu M; Xu H; He Q
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688553
[TBL] [Abstract][Full Text] [Related]
32. Heterogeneity induced GZMA-F2R communication inefficient impairs antitumor immunotherapy of PD-1 mAb through JAK2/STAT1 signal suppression in hepatocellular carcinoma.
Gao Y; Xu Q; Li X; Guo Y; Zhang B; Jin Y; Zhu C; Shen Y; Yang P; Shi Y; Jin R; Liu D; Ouyang Y; Liu X; Wang W; Chen D; Yang T
Cell Death Dis; 2022 Mar; 13(3):213. PubMed ID: 35256589
[TBL] [Abstract][Full Text] [Related]
33. Butein suppresses PD-L1 expression via downregulating STAT1 in non-small cell lung cancer.
Zhao L; Zhang W; Luan F; Chen X; Wu H; He Q; Weng Q; Ding L; Yang B
Biomed Pharmacother; 2023 Jan; 157():114030. PubMed ID: 36455456
[TBL] [Abstract][Full Text] [Related]
34. Tumor-derived extracellular vesicles containing long noncoding RNA PART1 exert oncogenic effect in hepatocellular carcinoma by polarizing macrophages into M2.
Zhou J; Che J; Xu L; Yang W; Zhou W; Zhou C
Dig Liver Dis; 2022 Apr; 54(4):543-553. PubMed ID: 34497040
[TBL] [Abstract][Full Text] [Related]
35. Upregulation of B7-H1 expression is associated with macrophage infiltration in hepatocellular carcinomas.
Chen J; Li G; Meng H; Fan Y; Song Y; Wang S; Zhu F; Guo C; Zhang L; Shi Y
Cancer Immunol Immunother; 2012 Jan; 61(1):101-8. PubMed ID: 21853301
[TBL] [Abstract][Full Text] [Related]
36. Self-delivery photothermal-boosted-nanobike multi-overcoming immune escape by photothermal/chemical/immune synergistic therapy against HCC.
Yang H; Mu W; Yuan S; Yang H; Chang L; Sang X; Gao T; Liang S; Liu X; Fu S; Zhang Z; Liu Y; Zhang N
J Nanobiotechnology; 2024 Mar; 22(1):137. PubMed ID: 38553725
[TBL] [Abstract][Full Text] [Related]
37. Extracellular vesicles containing PD-L1 contribute to CD8+ T-cell immune suppression and predict poor outcomes in small cell lung cancer.
Dou X; Hua Y; Chen Z; Chao F; Li M
Clin Exp Immunol; 2022 May; 207(3):307-317. PubMed ID: 35553630
[TBL] [Abstract][Full Text] [Related]
38. Abrine, an IDO1 inhibitor, suppresses the immune escape and enhances the immunotherapy of anti-PD-1 antibody in hepatocellular carcinoma.
Liang X; Gao H; Xiao J; Han S; He J; Yuan R; Yang S; Yao C
Front Immunol; 2023; 14():1185985. PubMed ID: 37334368
[TBL] [Abstract][Full Text] [Related]
39. Cancer cell-derived extracellular vesicles drive pre-metastatic niche formation of lymph node via IFNGR1/JAK1/STAT1-activated-PD-L1 expression on FRCs in head and neck cancer.
Han N; Zhou D; Ruan M; Yan M; Zhang C
Oral Oncol; 2023 Oct; 145():106524. PubMed ID: 37482043
[TBL] [Abstract][Full Text] [Related]
40. The role of extracellular vesicles in mediating progression, metastasis and potential treatment of hepatocellular carcinoma.
Yang N; Li S; Li G; Zhang S; Tang X; Ni S; Jian X; Xu C; Zhu J; Lu M
Oncotarget; 2017 Jan; 8(2):3683-3695. PubMed ID: 27713136
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
